Resolved No
🏛️ Politics
General
#40923
🎯 One of 2 candidates in the same event.
This market trades and resolves entirely on its own -- buying Yes here pays out only if
this specific outcome happens, regardless of what happens to the others. Prices across
the 2 candidates are not required to add up to 100% --
each one is priced independently, the same way Kalshi/Polymarket's own multi-candidate events work.
See all 2 candidates »
Will the FDA reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by August 31, 2026?
0.00Ᵽ
seed price — no trades yet
Call Yes
—
📡 Polymarket: 0%
Two different numbers on purpose: Polymarket's is the outside reference, Profet's is what actually moves credits here.
🔵 On Polymarket (at import): $2,002 volume
👁 6 views
⚡ Instant liquidity via Quick Bet
Price history
This platform
Polymarket (indicative)
Loading…
Polymarket's price is shown for reference only -- this platform's own order book sets its own price, and the two can diverge.
This market isn't open for trading.
Resolution
- Source
- Polymarket (via UMA optimistic oracle) ✓ Verified source
- Event cutoff
- Rules
- This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
Comments
Log in to join the discussion.
No comments yet -- be the first to say something.